CD40 and inflammatory bowel disease: Our current, novel findings further suggest that knocking out CD40 effectively attenuates some of the effects of MC-LR in the setting of pre-existing IBD and treatment with a CD40 receptor blocking peptide mirrors the effects seen with knocking out CD40.